Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (441-450 of 1,058) with videos related to

Pageof 106
Sort By:
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Cancer|November 23, 2006
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, et al.
The Journal of Clinical Investigation|March 1, 1991
Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasisR S Bresalier, Y Niv, J C Byrd, et al.
Journal of the American College of Cardiology|April 1, 1985
Ejection fraction response to supine exercise in asymptomatic aortic regurgitation: relation to simultaneous hemodynamic measurementsB M Massie, B L Kramer, D Loge, et al.
American Heart Journal|January 1, 1986
Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study GroupS Anderson, L Blanski, R C Byrd, et al.
Chempluschem|June 11, 2021
Synthesis and Characterization of the Potential Melt-Castable Explosive 3-(1,2,4-Oxadiazolyl)-5-Nitratomethyl IsoxazoleEric C Johnson, Tristen A Reid, Christopher W Miller, et al.
Cytotherapy|April 19, 2020
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemiaRajeswaran Mani, Girish Rajgolikar, Jessica Nunes, et al.
The Annals of Pharmacotherapy|November 29, 2013
Pharmacist-physician collaboration for diabetes care: cardiovascular outcomesAmanda Howard-Thompson, Michelle Z Farland, Debbie C Byrd, et al.
Blood|January 25, 2012
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Chempluschem|January 16, 2020
Bis(1,2,4-oxadiazolyl) Furoxan: A Promising Melt-Castable Eutectic Material of Low SensitivityEric C Johnson, Eric J Bukowski, Jesse J Sabatini, et al.
Pageof 106

Showing results (441-450 of 1,058) with videos related to

Sort By:
Pageof 106
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Cancer|November 23, 2006
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum, Jeffrey L Johnson, Donna Niedzwiecki, et al.
The Journal of Clinical Investigation|March 1, 1991
Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasisR S Bresalier, Y Niv, J C Byrd, et al.
Journal of the American College of Cardiology|April 1, 1985
Ejection fraction response to supine exercise in asymptomatic aortic regurgitation: relation to simultaneous hemodynamic measurementsB M Massie, B L Kramer, D Loge, et al.
American Heart Journal|January 1, 1986
Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study GroupS Anderson, L Blanski, R C Byrd, et al.
Chempluschem|June 11, 2021
Synthesis and Characterization of the Potential Melt-Castable Explosive 3-(1,2,4-Oxadiazolyl)-5-Nitratomethyl IsoxazoleEric C Johnson, Tristen A Reid, Christopher W Miller, et al.
Cytotherapy|April 19, 2020
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemiaRajeswaran Mani, Girish Rajgolikar, Jessica Nunes, et al.
The Annals of Pharmacotherapy|November 29, 2013
Pharmacist-physician collaboration for diabetes care: cardiovascular outcomesAmanda Howard-Thompson, Michelle Z Farland, Debbie C Byrd, et al.
Blood|January 25, 2012
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Chempluschem|January 16, 2020
Bis(1,2,4-oxadiazolyl) Furoxan: A Promising Melt-Castable Eutectic Material of Low SensitivityEric C Johnson, Eric J Bukowski, Jesse J Sabatini, et al.
Pageof 106